A fierce battle for Astra Zeneca – Swedish newspaper Svenska Dagbladet

Monday’s news about that the Company’s drug Brilinta, which is used for the treatment of acute coronary syndrome, type heart attack, also has a significant effect on long-term treatment to prevent stroke, myocardial infarction and cardiovascular death traded However, if one already established drug, but after the new study is expected to increase its potential considerably.

For shareholders, it was not so much new, more than the entire study was presented as the company broadly informed of the results in January .

For AstraZeneca is the research successes of Brilinta much needed. Last year sold Brilinta for $ 476 million, which placed the drug on 13 place internally. But last year it was only Brilinta and diabetesmdicinerna Onglyza and Bydureon who showed proper sales growth.

In other reported stagnant and in dollar terms dwindling sales. Expectations for Brilinta has been screwed up and some investment banks, as Swiss UBS expects that preparation can reach global sales of $ 5.5 billion in 2020. The average forecast is, however, at just under $ 2 billion.

” For AstraZeneca’s research successes of Brilinta much needed “

Astra Zeneca has is also a tough period ahead. For ulcer drug Nexium, which accounted for 14 percent of revenue last year, received Israeli Teva approval by the US FDA for a generic product in February and asthma medicine Symbicort, which accounted for 15 percent of revenue, ran head patents out last year, which is Teva in the starting blocks to get a copy in Europe.

And next year runs patent for the absolute bestseller, Crestor statin, with 21 percent of sales. On the cholesterol market meets Astra Zeneca additionally tough challenges from Amgen and Sanofi expected to get approval for two new drugs this year.

How halfway around AstraZeneca’s sales can be eroded quickly, so it is not so surprising that Astra Zeneca and the company’s CEO Pascal Soriot want to concentrate on the research portfolio. Management has also set a very ambitious goal which they said that sales will amount to the equivalent of 45 billion dollars to 2023, compared with last year’s $ 26 billion.

It would therefore like to recent research droughts and setbacks turned into its opposite. So expect a continued battle of research news from Astra Zeneca. Those who are most willing to share, as said UBS estimates that the pharmaceutical company has eight very interesting preparations, with combined annual sales potential of $ 25 billion, of which the major milestones of the research will be presented in the next 18 months.

But while last decade, there has been very difficult for Astra Zeneca, as well as for the entire industry, to bring some new bestseller by regulators narrow gates. A trend was possibly last year, when perhaps the toughest Agency, US FDA, released through 41 new substances, which was the highest level since 1996.

Apart from the Swedish horizon, it looks as if Astra’s management and Board with Leif Johansson at the tip, and the kind assistance from the British and Swedish politicians also have averted the immediate takeover threats. AstraZeneca shares are now trading just over 10 percent of Pfizer’s offer price. But it’s krona depreciation that explains this. Measured in pounds and for the main listing in London is the course still well below the bid level.

light of the continued very high employment rate and general price increases in the pharmaceutical industry as Astra Zeneca continued chased bytes.